Hikma Beats Amarin's 'Skinny Label' Patent Suit

By Dave Simpson (January 4, 2022, 11:05 PM EST) -- Hikma Pharmaceuticals USA Inc.'s generic heart drug does not infringe three patents underlying Amarin Pharma Inc.'s drug Vascepa, a Delaware federal judge ruled Tuesday, breaking with the recommendation from a magistrate judge.

U.S. District Judge Richard G. Andrews dismissed Amarin's patent infringement claims against Hikma, declining to adopt that portion of U.S. Magistrate Judge Jennifer L. Hall's report on the matter.

Amarin alleged in the "skinny label" case that Hikma induced doctors to infringe the patents by instructing them to use the Hikma generic for the use indications that Amarin patented. Skinny labels allow generic-drug makers to sell versions of drugs...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!